Who is sponsoring NCT04331314?

NCT04331314 is sponsored by Medical University of Graz.

What drugs are being tested in NCT04331314?

Interventions in NCT04331314: Use of Symbios Bone Graft Material, Algipore Bone Substitution Material.

What condition does NCT04331314 study?

NCT04331314 studies Bone Substitutes, Calcium Phosphates, Hydroxyapatite, Rhodophyta, Sinus Floor Augmentation.

Is NCT04331314 still recruiting?

NCT04331314 is currently completed. Last updated 2 April 2020.

Last reviewed 2020-04-02 · How we verify

NCT04331314

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biphasic Calcium Phosphate vs. Hydroxyapatite in Sinus Floor Elevation

Completed NA Last updated 2 April 2020

What this trial tests

NA trial testing Use of Symbios Bone Graft Material in Bone Substitutes in 20 participants. Completed in 28 October 2019.

Timeline

23 February 2015

Primary endpoint
20 March 2018

28 October 2019

Quick facts

Lead sponsor	Medical University of Graz
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	20
Start date	23 February 2015
Primary completion	20 March 2018
Estimated completion	28 October 2019

Drugs / interventions tested

Use of Symbios Bone Graft Material
Algipore Bone Substitution Material

Conditions studied

Bone Substitutes — all drugs for Bone Substitutes →
Calcium Phosphates — all drugs for Calcium Phosphates →
Hydroxyapatite — all drugs for Hydroxyapatite →
Rhodophyta — all drugs for Rhodophyta →

Sponsor

Medical University of Graz

Who can join

Adults 20 to 75, any sex, with Bone Substitutes or Calcium Phosphates. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Twenty patients scheduled for lateral-window sinus floor Elevation (SFE) are randomized into two groups: use of SYMBIOS® Biphasic Bone Graft Material (Group 1) or of Algipore® Bone Substitution Material (Group 2). Biopsies are taken 3 months after SFE and during implant surgery after 6 months. One ground section per biopsy (n=40) is stained, scanned, and histomorphometrically analyzed for new bone, old bone, soft tissue, graft, bone infiltration of graft, bone-to-graft contact, and penetration depth.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Medical University of Graz trials

Trials by the same sponsor.

NCT07498244 — Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) Patients · recruiting
NCT07492823 — Clinical Applicability of Liquid Biopsy in Chondrosarcoma · not yet recruiting
NCT07297615 — 3D Liver Volumetry · NA · not yet recruiting
NCT07588282 — The Effect of Psychoeducational Diagnosis Communication on Perception of Illness, Satisfaction, and Behavioral Intention · NA · recruiting
NCT07376096 — Liquid Biopsy in Germ Cell Tumors · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04331314 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Graz
Last refreshed: 2 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04331314.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing